Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) traded up NaN during mid-day trading on Wednesday . The company traded as high as $8.70 and last traded at $0.00. 657,623 shares changed hands during mid-day trading, an increase of Infinity from the average session volume of 0 shares.
A number of analysts recently issued reports on the company. Zacks Investment Research raised Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. HC Wainwright assumed coverage on Trillium Therapeutics in a research report on Monday, July 17th. They issued a “buy” rating and a $7.00 target price for the company. Finally, Cowen and Company reissued a “buy” rating on shares of Trillium Therapeutics in a research report on Wednesday, July 5th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $15.00.
A number of hedge funds have recently modified their holdings of the business. NEA Management Company LLC acquired a new position in Trillium Therapeutics in the second quarter valued at approximately $4,619,000. AWM Investment Company Inc. acquired a new position in Trillium Therapeutics in the second quarter valued at approximately $4,415,000. Janus Henderson Group PLC acquired a new position in Trillium Therapeutics in the second quarter valued at approximately $2,395,000. Tekla Capital Management LLC acquired a new position in Trillium Therapeutics in the second quarter valued at approximately $1,980,000. Finally, Sectoral Asset Management Inc boosted its stake in Trillium Therapeutics by 42.9% in the second quarter. Sectoral Asset Management Inc now owns 183,272 shares of the biotechnology company’s stock valued at $806,000 after acquiring an additional 55,000 shares during the period. Institutional investors own 47.97% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Trillium Therapeutics Inc. (TRIL) Trading NaN Higher” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/01/trillium-therapeutics-inc-tril-trading-nan-higher.html.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
What are top analysts saying about Trillium Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trillium Therapeutics Inc. and related companies.